2-HYDROXY-1,4-NAPHTHOQUINONE

Identification

Name
2-HYDROXY-1,4-NAPHTHOQUINONE
Accession Number
DB04744
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
NSC-27285 / NSC-52500 / NSC-8625
Categories
UNII
TLH4A6LV1W
CAS number
Not Available
Weight
Average: 174.1528
Monoisotopic: 174.031694058
Chemical Formula
C10H6O3
InChI Key
CSFWPUWCSPOLJW-UHFFFAOYSA-N
InChI
InChI=1S/C10H6O3/c11-8-5-9(12)10(13)7-4-2-1-3-6(7)8/h1-5,12H
IUPAC Name
2-hydroxy-1,4-dihydronaphthalene-1,4-dione
SMILES
OC1=CC(=O)C2=CC=CC=C2C1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AgmatineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Agmatine.Experimental, Investigational
AmiodaroneThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
AmrinoneThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Amrinone.Approved
AranidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Aranidipine.Approved, Investigational
AzelnidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Azimilide.Investigational
BarnidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Barnidipine.Approved
BencyclaneThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Benidipine.Approved, Investigational
BepridilThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Bepridil.Approved, Withdrawn
BioallethrinThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Bioallethrin.Approved, Experimental
BuspironeThe metabolism of Buspirone can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Carboxyamidotriazole.Investigational
CaroverineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Caroverine.Experimental
CilnidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Cilnidipine.Approved, Investigational
CinnarizineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational, Withdrawn
ClevidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Clevidipine.Approved, Investigational
CyclandelateThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Cyclandelate.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational, Vet Approved
DarodipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of 2-HYDROXY-1,4-NAPHTHOQUINONE resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Diltiazem.Approved, Investigational
DocetaxelThe metabolism of Docetaxel can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
DotarizineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Dotarizine.Investigational
EfonidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Efonidipine.Approved, Investigational
EperisoneThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Eperisone.Approved, Investigational
EthosuximideThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Ethosuximide.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved
FelodipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Fendiline.Withdrawn
Fish oilThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Fish oil.Approved, Nutraceutical
FlunarizineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Flunarizine.Approved
FluspirileneThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Fluspirilene.Approved, Investigational
FosphenytoinThe serum concentration of 2-HYDROXY-1,4-NAPHTHOQUINONE can be decreased when it is combined with Fosphenytoin.Approved, Investigational
GabapentinThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Gabapentin.Approved, Investigational
GallopamilThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Gallopamil.Investigational
IsradipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Isradipine.Approved, Investigational
LacidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Lamotrigine.Approved, Investigational
LercanidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Lercanidipine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Levetiracetam.Approved, Investigational
LidoflazineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Lidoflazine.Experimental
LoperamideThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Loperamide.Approved
LosartanThe metabolism of Losartan can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved
Magnesium sulfateThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Manidipine.Approved, Investigational
MentholThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Menthol.Approved
MethsuximideThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Methsuximide.Approved
MibefradilThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Mibefradil.Investigational, Withdrawn
NaftopidilThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Naftopidil.Investigational
NicardipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nicardipine.Approved, Investigational
NifedipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Niguldipine.Experimental
NiludipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nitrendipine.Approved, Investigational
NylidrinThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nylidrin.Approved
OtiloniumThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Otilonium.Experimental, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Vet Approved
PinaveriumThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Pinaverium.Approved
PrenylamineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Prenylamine.Withdrawn
ProgesteroneThe absorption of Progesterone can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Vet Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
SeletracetamThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Seletracetam.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved
SucralfateSucralfate can cause a decrease in the absorption of 2-HYDROXY-1,4-NAPHTHOQUINONE resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved, Investigational
TerodilineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Terodiline.Experimental
TetrahydropalmatineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TranilastThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Tranilast.Approved, Investigational
TrimebutineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Trimethadione.Approved
VerapamilThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Verapamil.Approved
VinpocetineThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Vinpocetine.Investigational
WIN 55212-2The therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with WIN 55212-2.Experimental
ZiconotideThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Approved
ZonisamideThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C10368
PubChem Compound
6755
PubChem Substance
46509125
ChemSpider
10430995
BindingDB
50049066
ChEBI
44401
ChEMBL
CHEMBL240963
HET
NQ
PDB Entries
2d0e

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.8 mg/mLALOGPS
logP0.99ALOGPS
logP0.98ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)8.02ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity48.15 m3·mol-1ChemAxon
Polarizability16.42 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8282
Caco-2 permeable+0.7343
P-glycoprotein substrateNon-substrate0.5873
P-glycoprotein inhibitor IInhibitor0.5
P-glycoprotein inhibitor IINon-inhibitor0.8995
Renal organic cation transporterNon-inhibitor0.8735
CYP450 2C9 substrateNon-substrate0.7873
CYP450 2D6 substrateNon-substrate0.9245
CYP450 3A4 substrateNon-substrate0.6861
CYP450 1A2 substrateInhibitor0.9206
CYP450 2C9 inhibitorInhibitor0.7177
CYP450 2D6 inhibitorNon-inhibitor0.8078
CYP450 2C19 inhibitorNon-inhibitor0.7624
CYP450 3A4 inhibitorNon-inhibitor0.9078
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5311
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9077
BiodegradationNot ready biodegradable0.8819
Rat acute toxicity3.0215 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9541
hERG inhibition (predictor II)Non-inhibitor0.931
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthoquinones. These are compounds containing a naphthohydroquinone moiety, which consists of a benzene ring linearly fused to a bezene-1,4-dione (quinone).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Naphthoquinones
Direct Parent
Naphthoquinones
Alternative Parents
Quinones / Aryl ketones / Vinylogous acids / Enols / Organic oxides / Hydrocarbon derivatives
Substituents
Naphthoquinone / Aryl ketone / Quinone / Vinylogous acid / Ketone / Enol / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
naphthoquinone (CHEBI:44401) / alpha-Naphthoquinones (C10368)

Drug created on September 11, 2007 11:49 / Updated on June 02, 2018 07:34